The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.
 
Frank M. Speetjens
No Relationships to Disclose
 
Marij JP Welters
No Relationships to Disclose
 
Marije Slingerland
No Relationships to Disclose
 
Peggy de Vos van Steenwijk
No Relationships to Disclose
 
Inge C.F.M. Roozen
No Relationships to Disclose
 
Sanne Boekestijn
No Relationships to Disclose
 
Nikki Loof
No Relationships to Disclose
 
Gijs G Zom
No Relationships to Disclose
 
Rob Valentijn
No Relationships to Disclose
 
Willem-Jan Krebber
Employment - ISA Pharmaceuticals
Leadership - ISA Pharmaceuticals
Stock and Other Ownership Interests - ISA Pharmaceuticals
Patents, Royalties, Other Intellectual Property - ISA Pharmaceuticals
 
Cornelis JM Melief
Employment - ISA Pharmaceuticals
Leadership - ISA Pharmaceuticals
Stock and Other Ownership Interests - ISA Pharmaceuticals
Patents, Royalties, Other Intellectual Property - ISA Pharamaceuticals BV
 
Dmitri V Filippov
Patents, Royalties, Other Intellectual Property - Leiden University
 
Hans Gelderblom
Research Funding - Daiichi (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)
 
Sjoerd H van der Burg
Consulting or Advisory Role - Aglaia BioMedical Ventures; Centre for Human Drug Research; DCPrime; ISA Pharmaceuticals; PCI Biotech
Research Funding - Frame Therapeutics; IO Biotech
Patents, Royalties, Other Intellectual Property - ISA Pharmaceuticals; Pamgene
 
Ferry Ossendorp
No Relationships to Disclose